Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases

BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number <4.0 signals/cell were re-classified as HER2 negative. This study aims to examine the response of Group 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Rakha, Emad A., Miligy, Islam M., Quinn, Cecily M., Provenzano, Elena, Shaaban, Abeer M., Marchiò, Caterina, Toss, Michael S., Gallagy, Grace, Murray, Ciara, Walshe, Janice, Katayama, Ayaka, Eldib, Karim, Badr, Nahla, Tanchel, Bruce, Millican-Slater, Rebecca, Purdie, Colin, Purnell, Dave, Pinder, Sarah E., Ellis, Ian O., Lee, Andrew H. S.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8144199/
https://ncbi.nlm.nih.gov/pubmed/33762723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01351-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados